PRESS RELEASE

Immcell and Celentyx collaboration demonstrates benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection

- Clinical trial supports IAD anti-viral indications
- IAD shown to increase NK cells in healthy donor cohort

DUBLIN, IRELAND/BIRMINGHAM, UK – 5th January, 2017 – Immcell Ltd, Ireland (“Immcell”) and Celentyx Ltd, UK (“Celentyx”), a pharmaceutical company with a focus on immune system mediated diseases, have jointly published the results of a collaboration in the field of anti-viral drug discovery.

The collaboration applied Celentyx’s powerful proprietary ImmuKnowlogy™ platform to investigate the action of Immcell’s immuno-modulatory drug, Inosine Acedoben Dimepranol (IAD), on immune cell subsets both in vitro and, in a clinical trial, in vivo. The pre-clinical studies demonstrated that IAD increased the proportion of regulatory T cells (Treg) and natural killer T cells (NKT) in vitro. A clinical trial was established to assess IAD impact in vivo and some increase in Treg and NKT cells was seen. More interesting was IAD’s ability to promote a rapid and durable rise in NK cells in vivo. These important results are reported in the latest edition of International Immunopharmacology and support IAD’s indicated benefit in immuno-compromised individuals and patients with viral infection.

“The partnership with Celentyx has been invaluable for our IAD development programme”, said James O’Daly, Founder & Managing Director, Immcell. “Celentyx CSO Professor John Gordon has been a constant support throughout our collaboration”.

"We are delighted to have the opportunity to work with Immcell," said Professor Nicholas Barnes, CEO of Celentyx. "We have now worked together for several years and it is very pleasing to see the successful evolution of this important project".

About Celentyx Ltd

Celentyx is a pharmaceutical R&D and service company with a focus on diseases relevant to the human immune system e.g. cancers susceptible to treatment by immuno-oncology checkpoint inhibitors.

Celentyx’s ImmuKnowlogy™ research services allows rapid analysis of drug action on human immune cells and tissues at the highest levels of resolution, enabling partners to identify new development paths for clinical-stage drug candidates, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system. The company has established partnerships with a number of medium and large pharmaceutical companies.
About Immcell Ltd

Immcell Ltd is a privately owned life science company operating alongside its sister company Kora Corporation Ltd (trading as Kora Healthcare). Immcell is a subsidiary of Immdal Ltd the Holding Company for the Group.

[www.immcell.ie](http://www.immcell.ie)

Immcell Pharma is the pharmaceutical division of Immcell whose primary focus is in the identification, development and commercialisation of new innovative products in the areas of inflammatory disease for development and licensing to third parties.

For more information, please visit Celentyx's website at [www.celentyx.com](http://www.celentyx.com) or contact:

Catherine Brady, PhD
Chief Operating Officer
E-mail: catherine.brady@celentyx.com